Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02124759 · ClinicalTrials.gov registry record · Phase 2
Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02124759 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 20 participants.
The verdict
NCT02124759, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine insulin sensitivity in individuals that are lean normal glucose tolerant subjects after consumption of a normal low fat diet and after a high fat diet and to explore the effects of high fat consumption on the intestinal microbiome, and metabolic endotoxemia.( Aim 1 of the protocol, a separate record is available for Aim 2)
Interventions
- DRUG Maltodextrin
- DRUG Synbiotic
- DRUG Sevelamer
- OTHER Low Fat diet
- OTHER High Fat diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-04-02 |
| Est. Completion | 2020-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02124759
The ClinicalTrials.gov registry entry for NCT02124759 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Maltodextrin is the first listed.
NCT02124759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02124759 about?
NCT02124759 is a clinical study titled "Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)". The purpose of this study is to determine insulin sensitivity in individuals that are lean normal glucose tolerant subjects after consumption of a normal low fat diet and after a high fat diet and to explore the effects of high fat consumption on the intestinal microbiome, and metabolic endotoxemia....
What is the current status of trial NCT02124759?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2014-04-02. Estimated completion is 2020-03-30.
What interventions are being tested in trial NCT02124759?
The interventions under investigation include: Maltodextrin (DRUG), Synbiotic (DRUG), Sevelamer (DRUG), Low Fat diet (OTHER), High Fat diet (OTHER).
Who is sponsoring clinical trial NCT02124759?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.